Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/65309
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBagchi, Arka-
dc.contributor.authorBiswas, Arunima-
dc.date.accessioned2025-02-07T04:54:23Z-
dc.date.available2025-02-07T04:54:23Z-
dc.date.issued2025-03-
dc.identifier.issnISSN: 0975-0959 (Online) ;ISSN: 0301-1208 (Print)-
dc.identifier.urihttp://nopr.niscpr.res.in/handle/123456789/65309-
dc.description213-221en_US
dc.description.abstractIn this review, we explore the potential of cAMP-Phosphodiesterase 4 (PDE4), a key intracellular enzyme, as a therapeutic target for cancer treatment. cAMP-PDEs play a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP), an essential second messenger involved in cell proliferation and metastasis in a tissue-specific manner depending on the PDE isoforms present. Elevated PDE4 expression has been reported in cancers such as breast, cervical, and lung cancer. Specific PDE4 subtypes are recognized for their roles in cancer progression, making PDE4 inhibitors promising candidates for therapeutic intervention. This review examines the role of PDE4 in cancer progression and highlights the therapeutic potential of studied PDE4 inhibitors.en_US
dc.language.isoenen_US
dc.publisherNIScPR-CSIR, Indiaen_US
dc.sourceIJBB Vol.62(03) [March 2025]en_US
dc.subjectcAMPen_US
dc.subjectCancer progressionen_US
dc.subjectInhibitorsen_US
dc.subjectMetastasisen_US
dc.subjectPhosphodiesterase 4en_US
dc.subjectRoflumilasten_US
dc.subjectRolipramen_US
dc.titlePhosphodiesterase 4 as a candidate therapeutic target of canceren_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.56042/ijbb.v62i3.13103en_US
Appears in Collections:IJBB Vol.62(03) [March 2025]

Files in This Item:
File Description SizeFormat 
IJBB Vol.62(3) 213-221.pdf1.28 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.